MRM Health NV


MRM Health NV is a clinical-stage biopharmaceutical company that develops microbiome-based live biotherapeutic products for the treatment of chronic inflammatory diseases and to augment immune-oncology therapies. Founded in 2019 as a spin-off from the Flanders Institute for Biotechnology and Ghent University. MRM Health is developing MH002, a microbial consortium candidate for the treatment of ulcerative colitis, and operates a proprietary co-fermentation platform CORAL.

History

The technology underlying MRM Health originates from microbiome research carried out in Ghent. ProDigest, founded in 2008 by Sam Possemiers, developed in vitro gut models and strain‑selection methods that informed the rational design of microbial consortia. MRM Health was established in 2019 as a translational spin‑off from VIB and Ghent University to advance these discoveries toward clinical development.
In 2019, the company completed a Series A financing round of approximately €14 million, with participation from Ackermans & van Haaren, DuPont Nutrition & Biosciences, OMX Europe Venture Fund, and company management.
In 2020 MRM Health entered a collaboration with DuPont Nutrition & Biosciences to explore microbiome solutions for metabolic disease programs.
In 2025, the company closed a €55 million Series B financing round led by Biocodex, with new investors also including Athos and BNP Paribas Private Fortis Equity. It announced a strategic development and manufacturing agreement with Biocodex to support clinical development and scale-up of its CORAL platform.

Research and technology

MRM Health develops live biotherapeutic products composed of defined bacterial consortia that are intended to restore microbial balance, strengthen intestinal barrier function, and modulate immune responses.  The company’s proprietary CORAL platform enables co‑fermentation of multiple bacterial strains in a single process, producing a homogeneous drug substance intended to be scalable and manufacturable to GMP standards.

MH002

MH002 is MRM Health’s lead programme: a rationally designed six-strain microbial consortium developed for the treatment of ulcerative colitis. The product is intended to restore a healthy gut microbial balance, reinforce the intestinal barrier and rebalance immune activity without broad immunosuppression.  Early clinical studies including Phase 2a trials in ulcerative colitis and the orphan condition pouchitis reportedly demonstrated a favorable safety profile and preliminary signs of efficacy.

Other programs

Beyond MH002, MRM Health is developing additional consortia for Crohn’s disease and metabolic disorders, and exploring applications to enhance cancer immunotherapies.  The company also maintains research activities in animal health in collaboration with partners. Several preclinical and IND‑enabling programmes are reported to be in development.